BDX — BCAL Diagnostics Income Statement
0.000.00%
- AU$36.49m
- AU$32.97m
- AU$2.79m
- 37
- 16
- 55
- 29
Annual income statement for BCAL Diagnostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.257 | 0.442 | 0.275 | 0.7 | 2.79 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.683 | 1.14 | 1.8 | 4.1 | 7.9 |
Operating Profit | -0.427 | -0.697 | -1.53 | -3.4 | -5.11 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.43 | -0.696 | -1.52 | -3.39 | -5.06 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.43 | -0.696 | -1.52 | -3.39 | -5.06 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.43 | -0.696 | -1.52 | -3.39 | -5.06 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.43 | -0.696 | -1.52 | -3.39 | -5.06 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.003 | -0.005 | -0.016 | -0.024 |
Dividends per Share |